The US healthcare system is a paradox: it spends more per person than any other wealthy nation, leads the world in medical research, and delivers some of the best specialized care available, yet it ranks last overall among high-income countries in performance. Whether US healthcare is “good” depends entirely on what you’re measuring and, often, on who you are within the system.
How the US Ranks Against Peer Nations
The Commonwealth Fund’s 2024 comparison of 10 high-income countries placed the United States dead last in overall healthcare performance. The other nine countries (including Australia, Germany, the UK, Sweden, and France) clustered relatively close together. The US was a clear outlier, spending far more of its GDP on healthcare yet producing the worst results by most measures.
The US ranked last in three of the five major categories: access to care, health equity, and health outcomes. It tied for last with New Zealand on equity, with the widest income-based gaps in affordability and the highest rates of patients reporting unfair treatment based on race or ethnicity. The one bright spot was care process, where the US ranked second overall, driven by strong preventive services like mammograms and flu vaccinations and a focus on patient safety protocols.
What the US Does Well
If you have good insurance and access to a major medical center, the quality of care in the US can be exceptional. Cancer treatment is a clear example. Data from the CONCORD study published in The Lancet Oncology found that women diagnosed with breast cancer in the US had a five-year survival rate of 84%, compared to a 73% weighted average across 17 European countries. Similar advantages show up in prostate cancer and certain other cancers where early detection and aggressive treatment protocols make a measurable difference.
The US also dominates global medical innovation. It accounts for roughly 30% of all research and development spending worldwide, and in 2022 it led all OECD countries in biotechnology R&D at $117.1 billion. Many of the world’s new drugs, devices, and treatment protocols originate from US institutions. If you need cutting-edge care for a rare or complex condition, the US is often where that care exists first.
Wait times for specialists are another area where the US performs reasonably well. Across OECD countries, about 52% of patients wait a month or longer to see a specialist. In Canada and the UK, more than 10% of patients report waiting over a year. The US generally offers faster access to specialists and elective procedures than countries with single-payer systems, though this advantage applies mainly to people with adequate insurance coverage.
Where the System Falls Short
Life expectancy tells the broadest story. In 2024, Americans could expect to live 79.0 years at birth, which is 3.7 years below the average of comparable wealthy nations (82.7 years). American men live to about 76.5, compared to 80.5 in peer countries. American women live to 81.4, compared to 84.8. These gaps persist even at age 65, which means they aren’t explained solely by gun violence, car accidents, or other causes that disproportionately affect younger people.
The US also has the highest rates of preventable and treatable deaths among the 10 countries the Commonwealth Fund studied. These are deaths from conditions where timely, effective healthcare should keep people alive: things like diabetes complications, treatable infections, and cardiovascular disease caught early enough to manage.
Maternal mortality is another persistent problem. The CDC’s provisional data for the 12-month period ending December 2025 puts the US maternal mortality rate at 16.6 deaths per 100,000 live births. Most Western European countries report rates between 2 and 8 per 100,000. The US rate is roughly double to triple what peer nations experience, and the gap is even wider for Black women.
The Cost Problem
Americans spent $15,474 per person on healthcare in 2024, totaling $5.3 trillion nationally. That figure is roughly double what most other wealthy countries spend per capita. Yet this spending doesn’t translate into better population health. The US pays more for nearly everything: hospital stays, prescription drugs, physician salaries, and administrative overhead from its fragmented insurance system.
The gap between spending and outcomes is the core inefficiency. Countries like Australia and Switzerland achieve longer life expectancies, lower maternal mortality, and better chronic disease management while spending significantly less. The US system generates enormous revenue for hospitals, insurers, pharmaceutical companies, and device manufacturers, but the returns for patients as a whole are poor relative to the investment.
Access Depends on Who You Are
About 27.5 million Americans (8.2% of the population) had no health insurance during the first half of 2025. Being uninsured in the US means something different than in most peer nations, where universal coverage ensures at least basic access. Uninsured Americans face the full cost of care, which leads many to delay treatment, skip medications, or avoid the doctor entirely until a condition becomes an emergency.
Even among the insured, affordability remains a widespread problem. High deductibles, copays, and out-of-network billing mean that having insurance doesn’t guarantee you can afford to use it. Americans are more likely than people in other wealthy countries to report skipping care because of cost. They’re also more likely to lack a regular doctor or a consistent place to receive care, and they have fewer options for after-hours treatment compared to patients in peer nations.
Income and race shape the experience dramatically. Wealthier Americans with employer-sponsored insurance or the ability to pay out of pocket can access world-class care with relatively short wait times. Lower-income Americans, particularly those in states that didn’t expand Medicaid, face a system that looks nothing like what their wealthier neighbors experience. The result is one of the largest equity gaps among high-income countries.
The Bottom Line on Quality
US healthcare is simultaneously among the best and worst in the developed world. The clinical quality of care, once you’re in the system and receiving treatment, is genuinely strong. Preventive screening rates are high, patient safety protocols are robust, and specialized care for complex conditions is often unmatched globally. The system’s failures are in who can access that care, at what cost, and what happens to population health when millions of people can’t.
If you’re asking whether a well-insured American gets good healthcare, the answer is generally yes. If you’re asking whether the US healthcare system produces good results for its population given what it spends, the evidence consistently says no. The US has the most expensive healthcare system in the world and some of the worst health outcomes among wealthy nations. Both of those things are true at the same time, and understanding that contradiction is the only honest way to answer the question.